FPT-SOFTWARE
12.1.2024 05:26:33 CET | Business Wire | Press release
Global tech corporation FPT affirms its position as a world-class technology enabler for complex business challenges and opportunities with long-term goals defined for 2024 onwards. FPT aims to achieve USD 5 billion in revenue from global IT services in 2030 and reach billion-dollar milestones from a single market, a single vertical industry, and a single contract.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240111379315/en/
From left to right: FPT Software Chairwoman Chu Thi Thanh Ha, FPT CEO Nguyen Van Khoa, FPT Software CEO Pham Minh Tuan (Photo: Business Wire)
On track with this direction, FPT recently became the first Vietnam-headquartered tech firm to surpass one billion USD in revenue from global IT services in 2023. The company embarked on the global expansion journey with the establishment of its subsidiary FPT Software in 1999. Since then, FPT has evolved from developing simple applications to implementing core IT services for its clients; transitioned from a services provider to a comprehensive solution provider; and progressed to higher stages in the technology value chain, with digital transformation and legacy modernization included in its offerings. To achieve its future goals, FPT will leverage its strengths in technical expertise and industry know-how, skilled IT talents, and the growing prominence of its home country Vietnam.
"In the past, FPT had to proactively seek partnerships, but now many big corporations are heading to Vietnam and FPT. Vietnam is rising as a new destination for global businesses. As Vietnam’s pioneering IT firm, we want to reach new heights in the semiconductor industry and artificial intelligence (AI). The future of Vietnam and the world will revolve around semiconductors and AI,” said FPT Chairman Dr. Truong Gia Binh.
"At FPT Software, we believe that world-class stature is built from world-class people. Over the past 25 years, we have strengthened the company's foundation by fostering a one-team spirit, a lifelong learning culture, and a happy working environment. Moving forward, we will continue promoting the development of technology, creativity, domain expertise, and embrace culture and diversity for our workforce of 30,000 talented individuals to keep up with growing market demand and global standards," said FPT Software Chairwoman Chu Thi Thanh Ha.
"Entering the new era as a world-class company, FPT Software is well-positioned to accompany our clients in projects worth millions or billions of dollars. We are committed to developing our high quality global IT workforce to better serve businesses in high-growth fields such as automotive, healthcare, insurance, supply chain, finance, and utilities. We will also embed AI into all services and solutions to enhance agility, productivity, quality and accelerate delivery time for our clients worldwide,” said FPT Software CEO Pham Minh Tuan.
With a track record of success and extensive experience gained over the years, FPT has established itself as a trusted partner to drive advancements in fast-growing fields. In 2023, FPT is one of three companies in Southeast Asia to join SAP’s Regional Strategic Services Partner (RSSP) in the Asia Pacific and Japan region. With over 10 years of experience in automotive software, FPT has built a strong team of over 4,000 engineers and experts for this domain, serving more than 150 clients, including renowned global brands such as Honda, Hyundai, Volvo, VinFast, Ford, Yazaki, LG, Panasonic, NXP. In December 2023, the subsidiary FPT Automotive was officially launched in the United States, after maintaining a growth rate of 40% in recent years as a unit under FPT Software, contributing significantly to its achievement of one billion USD in revenue from the global IT services segment.
About FPT Corporation and FPT Software
FPT Corporation is a global technology corporation and a leader in consulting, providing, and deploying technology and telecommunications services and solutions.
FPT Software, a subsidiary of FPT Corporation, is a global technology and IT services provider headquartered in Vietnam, with $1 billion in revenue (2023) and over 30,000 employees in 30 countries.
The company champions complex business opportunities and challenges with its world-class services in Advanced Analytics, AI, Digital Platforms, Cloud, Hyperautomation, IoT, Low-code, and so on. It has partnered with over 1,000+ clients worldwide, 91 of which are Fortune Global 500 companies in Aviation, Automotive, Banking, Financial Services and Insurance, Healthcare, Logistics, Manufacturing, Utilities, and more. For more information, please visit https://fptsoftware.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240111379315/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom